Emergent BioSolutions Inc.
NYSE:EBSBiotechnology
-$0.21 today
- Market cap
- $282.78M
- Beta
- 2.33
- P/E (TTM)
- -47.9
- EPS (TTM)
- -$0.17
Volume 0.82M
Average 0.78M
EBS Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Emergent BioSolutions Inc.NYSE: EBS
Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026
Net change in cash turns negative
Q1 FY2026 net change in cash was -$47.6M, compared with $47.2M a year earlier. Trailing-twelve-month net change in cash was $8.7M. Over 3 fiscal years it compounded at +16.0% a year.
Context
- Net change in cash amounted to 13.9% of revenue in FY2025, up 13.3 pp from a year earlier.
- Net change in cash increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly net change in cash holds near -$47.6M or moves back toward the trailing-twelve-month quarterly average of $2.18M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- 103.5M USD
- Year-over-year change
- +1796.7%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 103.5M | +1796.7% |
| FY2024 | 2024-12-31 | (6.1M) | +98.9% |
| FY2023 | 2023-12-31 | (530.9M) | -900.8% |
| FY2022 | 2022-12-31 | 66.3M | +246.7% |
| FY2021 | 2021-12-31 | (45.2M) | — |
Net Change in Cash vs competitors
How EBS compares with its peers on the latest reported figures
- Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -88.2% is the 6th highest of 11, against a peer median of -60.3%.
- Net change in cash amounts to 1.3% of revenue for EBS, versus a peer median of 9.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $205.9M USD | +7485.2% | -50.8% | — | |
| LTM Mar 2026 | $88.47M USD | -31.9% | — | 152.7% | |
| LTM Mar 2026 | $42.08M USD | +258.5% | — | 83.7% | |
| LTM Mar 2026 | $41.53M USD | +137.1% | — | 9.9% | |
| LTM Mar 2026 | $35.1M USD | +1528.7% | -56.4% | — | |
| LTM Mar 2026 | $21.32M USD | -205.5% | — | 7.1% | |
| LTM Mar 2026 | $18.44M USD | -187.0% | +55.0% | 3.6% | |
| LTM Mar 2026 | $16.71M USD | -190.8% | -53.6% | 17.8% | |
| LTM Mar 2026 | $8.7M USD | -88.2% | +16.0% | 1.3% | |
| LTM Mar 2026 | CA$7.46M CAD | -123.4% | — | 0.8% | |
| LTM Mar 2026 | $1.91M USD | -88.7% | — | — | |
| Peer median (excluding EBS) | — | -60.3% | -52.2% | 9.9% | |
Competitors are the stored peer set for EBS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 230.9M | (211.6M) | (760.5M) | (190.6M) | 52.6M |
| Depreciation & Amortization | 123.8M | 143.3M | 125.1M | 108.8M | 95.8M |
| Deferred Income Tax | 46.9M | (28.6M) | (8.9M) | (5.5M) | (4M) |
| Stock-Based Compensation | 42.4M | 45.1M | 23.1M | 18M | 16.2M |
| Change in Working Capital | (156.4M) | (2.1M) | (70.3M) | 88.7M | (22.4M) |
| Accounts Receivables | (48.2M) | 118.1M | (21.6M) | (24.4M) | 25.5M |
| Inventory | (44M) | (57.1M) | 600K | (24.5M) | (30.3M) |
| Accounts Payables | (2.5M) | (14M) | 10.6M | (33M) | (8.4M) |
| Other Working Capital | (61.7M) | (49.1M) | (59.9M) | 170.6M | (9.2M) |
| Other Non-Cash Items | 33.5M | 19.8M | 485.2M | 39.3M | 32.4M |
| Operating Cash Flow | 321.1M | (34.1M) | (206.3M) | 58.7M | 170.6M |
| Capital Expenditures | (225M) | (115.8M) | (51.6M) | (22.9M) | (13.8M) |
| Acquisitions (Net) | 0 | 0 | 270.2M | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (265.5M) | (6.3M) | 148.1M | 83.2M |
| Investing Cash Flow | (225M) | (381.3M) | 212.3M | 125.2M | 69.4M |
| Debt Repayment | (35.9M) | 564.2M | (543.4M) | (198.4M) | (112.5M) |
| Common Stock Issued | 0 | 0 | 8.4M | 9.3M | 2.2M |
| Common Stock Repurchased | (106M) | (82.1M) | 0 | 0 | (24.9M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 900K | (900K) | (700K) | (900K) | (1.4M) |
| Financing Cash Flow | (141M) | 481.2M | (535.7M) | (190M) | (136.6M) |
| Effect of Forex Changes | (300K) | 500K | (1.2M) | 0 | 100K |
| Net Change in Cash | (45.2M) | 66.3M | (530.9M) | (6.1M) | 103.5M |
| Free Cash Flow | 96.1M | (149.9M) | (257.9M) | 35.8M | 156.8M |
Emergent BioSolutions Inc.
NYSE:EBS
Intrinsic Alpha fair value
Locked
Current Price
$5.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.